| Outcome Measures: |
Primary: Subject incidence of treatment-emergent adverse events, Physical examinations, vitals, laboratory analytes, and ECGs, 43 Days (Cohorts 1, 3, 5 and 7), 57 Days (Cohorts 2, 4, 6 and 9) or 71 Days (Cohort 8).|Subject incidence of anti-AMG 876 antibodies, Laboratory analytes, 43 Days (Cohorts 1, 3, 5 and 7), 57 Days (Cohorts 2, 4, 6 and 9) or 71 Days (Cohort 8). | Secondary: AMG 876 serum PK parameters, Concentration-time profiles for AMG 876, 43 Days (Cohorts 1, 3, 5 and 7), 57 Days (Cohorts 2, 4, 6 and 9) or 71 Days (Cohort 8).|Pharmacodynamic parameters, Concentration of fasting glucose, insulin, and C-peptide levels; Concentration-time profiles and AUC for metabolic parameters (eg, glucose, insulin, C peptide, glucagon, and non-esterified fatty acid concentrations); Fasting lipid levels (total cholesterol, low-density lipoprotein \[LDL\], high-density lipoprotein \[HDL\], and triglycerides); The following 7-point SMBG parameters: pre-meal average blood glucose, post-meal average blood glucose, 7-point average blood glucose, post-meal excursion, post-meal excursion average; Body weight, 24 hour weighted mean glucose(cohort 9 only), 43 Days (Cohorts 1, 3, 5 and 7), 57 Days (Cohorts 2, 4, 6 and 9) or 71 Days (Cohort 8).
|
| Locations: |
Research Site, Chula Vista, California, 91911, United States|Research Site, Miramar, Florida, 33025, United States|Research Site, Overland Park, Kansas, 66212, United States|Research Site, Cincinnati, Ohio, 45255, United States|Research Site, San Antonio, Texas, 78209, United States|Research Site, Renton, Washington, 98057, United States
|
